Clinical Research Directory
Browse clinical research sites, groups, and studies.
Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Sponsor: Centre Hospitalier Universitaire de Nīmes
Summary
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease. In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
Official title: Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Key Details
Gender
All
Age Range
15 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1150
Start Date
2019-05-22
Completion Date
2028-06
Last Updated
2024-05-14
Healthy Volunteers
No
Conditions
Interventions
Blood sample
2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
Locations (28)
CHU d'Amiens
Amiens, France
CHU de Besancon
Besançon, France
CHU de Bordeaux
Bordeaux, France
CHU de Caen
Caen, France
CHU de Clermont Ferrand
Clermont-Ferrand, France
Hopital Henri Mondor
Créteil, France
CHU de Dijon
Dijon, France
CHU de Grenoble
Grenoble, France
CHU de Lille
Lille, France
CHU de Limoges
Limoges, France
CHU de Lyon
Lyon, France
Hopital Timone
Marseille, France
CHU de Montpellier
Montpellier, France
CHU de Nancy
Nancy, France
CHU de Nice
Nice, France
CHU de Nimes
Nîmes, France
Fondation Rothschild
Paris, France
Hopital Pitie Salpetriere
Paris, France
Hopital Saint Antoine
Paris, France
CH de Poissy
Poissy, France
CHU de Potiers
Potiers, France
CHU de Rennes
Rennes, France
CHU de Rouen
Rouen, France
CHU de Saint Etienne
Saint-Etienne, France
CHU de Strasbourg
Strasbourg, France
CHU de Toulouse
Toulouse, France
CHU de Tours
Tours, France
CHU de Martinique
Fort-de-France, Martinique